APA (7th ed.) Citation

Heudobler, D., Heudobler, D., Schulz, C., Fischer, J. R., Staib, P., Wehler, T., . . . Reichle, A. (2021). A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Heudobler, Daniel, et al. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers Media S.A, 2021.

MLA (9th ed.) Citation

Heudobler, Daniel, et al. A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung). Frontiers Media S.A, 2021.